drugset / Trial / NCT07362940
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
NaSequentialOpen-labelTreatment
Summary
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.
Timeline
- Start
- 2025-11-27
- Primary completion
- 2027-07-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dositinib | Small molecule | 80 mg | Oral |
| Subject | Dositinib | Small molecule | 160 mg | Oral |
| Subject | GEN-725 | Unknown | 6 mg | Oral |
| Subject | GEN-725 | Unknown | 9 mg | Oral |